Illumina Grows Clinical IVD Portfolio with Introduction of NextSeq™ 550Dx System and Expanded Use of MiSeq™Dx System
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) announced today the introduction of its NextSeq™ 550Dx instrument, the company’s second FDA-regulated and CE-IVD marked next-generation sequencing (NGS) system. The company also announced that the intended use for the MiSeq™Dx instrument has been updated to include the use of DNA libraries generated from formalin-fixed paraffin embedded (FFPE) tissues,... Read more